Its the kind of signal that usually triggers more research, not the kind that should make people toss their medication in the trash
Effect of GLP-1 Treatment on Bone Turnover in normal, Type 2 Diabetic, and Insulin-Resistant States
[DOI] [PubMed] [Google Scholar] 12.Habtemariam S
NICE guidelines for type 2 diabetes (NG28) recommend reviewing GLP-1 treatment at around 6 months and continuing only if there has been a meaningful reduction in HbA1c (typically at least 11 mmol/mol [1%]) and weight loss of at least 3% of initial body weight
Among 79,486 matched participants, GLP-1 receptor agonist use is associated with a lower risk of RVO (hazard ratio
Alternative GLP-1 formulations, dose adjustments, or switching to different weight loss medications may be appropriate